Abstract
Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers.
Background: PBT434 is a novel, brain-penetrant, small molecule inhibitor of α-synuclein aggregation. In transgenic animal models of Parkinson disease (A53T) and MSA (PLP-α-Syn), PBT434 reduced α-synuclein aggregation, preserved neurons and improved motor function. Glial cell inclusions were also reduced in a murine MSA model. PBT434 is thought to act by redistributing reactive iron across membranes, thereby blocking intracellular protein aggregation and oxidative stress. The affinity of PBT434 for iron is greater than that of α-synuclein but lower than that of iron trafficking proteins, e.g., ferritin.
Design/Methods: In this randomized, double-blind, placebo-controlled first in human study, subjects received oral single ascending doses (SAD; n=8) or multiple ascending doses (MAD; n=10) of PBT434. Serial plasma samples were collected over 72 hour post-dose in the SAD and over 12 and 96 hours post-dose on Days 1 and 8, respectively, in the MAD portions of the study. Safety was assessed between cohorts with physical examination, vital signs, adverse events, laboratory tests and 12-lead ECGs.
Results: PBT434 demonstrated approximately proportional pharmacokinetics over the dose range studied based on dose normalized PK parameters. The mean(CV%) AUCinf was 896.7(27.8), 1587(19.0) and 6494(35.9) ng•hr/mL and the mean(CV%) Cmax was 493.3(33.3), 802.7(28.1) and 2978(46.5) ng/mL for 50, 100 and 300 mg, respectively. PBT434 was rapidly and extensively absorbed after oral administration with a median Tmax of 1 to 1.25 hours. PBT434 was well tolerated following single doses up to 300 mg with infrequent AEs that were mild. No serious adverse events were reported. No laboratory or ECG abnormalities were detected.
Conclusions: PBT434 demonstrated approximately proportional pharmacokinetics up to 300 mg and was well tolerated in healthy volunteers. PBT434 is an oral small molecule drug candidate with potential for treating synucleinopathies such as Parkinson disease and MSA.
Disclosure: Dr. Stamler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Auspex Pharmaceuticals. Dr. Bradbury has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prana Biotechnology and Teva. Dr. Wong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prana. Dr. Offman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prana.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.